Selective silencing of mammalian gene expression has recently been achieved using short interfering RNA (siRNA). Synthetic siRNA targets homologous mRNA for degradation and the process is highly efficient. Here we demonstrate siRNA silencing of pathogenic viral gene expression. As a well characterized model we chose cervical carcinoma cells positive for human papillomavirus type 16. Over 90% of human cervical cancers are positive for papillomavirus and abnormal cell proliferation is driven by co-operative effects of viral E6 and E7 genes. We sought to silence HPV E6 and E7 gene expression using siRNAs to target the respective viral mRNAs. Our results indicate selective degradation of E6 and E7 mRNAs. Silencing was sustained for at least 4 days following a single dose of siRNA. E6 silencing induced accumulation of cellular p53 protein, transactivation of the cell cycle control p21 gene and reduced cell growth. In contrast, E7 silencing induced apoptotic cell death. HPV-negative cells appeared unaffected by the anti-viral siRNAs. Thus we demonstrate for the first time (i) that siRNA can induce selective silencing of exogenous viral genes in mammalian cells, and (ii) that the process of siRNA interference does not interfere with the recovery of cellular regulatory systems previously inhibited by viral gene expression.
Introduction
Abnormal gene expression is linked with the pathogenesis of many diseases. The predicted therapeutic advantages of interfering with the expression of pathogenic genes has stimulated the development of novel strategies for selective gene silencing, including anti-sense strategies for post-transcriptional gene silencing. A new process termed RNA interference has recently been described in which double stranded RNA targets homologous mRNA for endonucleolytic cleavage and degradation (Fire et al., 1998; Zamore et al., 2000; Elbashir et al., 2001; Caplen et al., 2001 ; reviewed in Sharp, 2001; Carthew, 2001) . The process, first discovered in non-mammalian systems, effectively blocks gene expression at the post-transcriptional level and is several orders of magnitude more efficient than antisense or ribozyme treatment (Elbashir et al., 2001 ). The current model for the mechanism of RNA interference is based upon the observation that the introduced dsRNA recognizes homologous mRNA sequences, and is bound and cleaved by endonuclease RNase III to generate double-stranded 21-and 22-nucleotide products (Knight and Bass, 2001; Ketting et al., 2001) . These small interfering RNAs (siRNAs) remain stably complexed with the endonuclease plus associated proteins and initiate degradation of further homologous mRNAs. Thus siRNA duplexes serve as primers to transform the target mRNA into more double-stranded siRNA molecules and the process of RNA interference is self-replicative (Lipardi et al., 2001) . It has now been demonstrated that introduction of 21-nucleotide siRNA intermediates is sufficient to initiate RNA interference (Elbashir et al., 2001) . This is important for the application of RNA interference to mammalian systems because longer dsRNA molecules induce the non-specific interferon response.
Here we ask if siRNA can be employed to silence exogenous viral gene expression in mammalian cells. Many factors can protect a given mRNA from RNA interference in mammalian cells and the vulnerability of viral mRNAs to siRNA silencing is unknown. We selected human papillomavirus (HPV) as a clinically relevant viral target. High risk types of HPV are causally linked with initiation and malignant progression of human cervical carcinoma and encode at least three oncoproteins, namely E5, E6 and E7 (reviewed in zur Hausen, 2000; Thomas et al., 1999; McMurray et al., 2001) . Of these E6 and E7 are best understood. For our studies we employed CaSKi and SiHa, two human cervical carcinoma cell lines positive for high risk type HPV16 and well characterized as models for the study of HPV-induced cell transformation (Hengstermann et al., 2001; Butz et al., 1995 Butz et al., , 1996 Scheffner et al., 1991; Hietenan et al., 2000; Baker et al., 1987) . The E6 and E7 gene products of HPV are pleiotropic and appear to exert their transforming properties by binding, directly or indirectly, to cellular proteins linked with cell growth regulation. Of particular importance are the interactions of E6 with p53, and of E7 with the retinoblastoma protein (pRb). The p53 and pRb proteins are key tumour suppressors and cell cycle inhibitors in mammalian cells. Binding of E6 to p53 is mediated by E6-associated protein ligase (E6-AP) and targets p53 for ubiquitination and proteosomal degradation (Scheffner et al., 1990 (Scheffner et al., , 1993 . E6 may also decrease p53 capacity for growth inhibitory gene transactivation by suppressing the co-activators CBP and p300 (Patel et al., 1999) . In parallel, E7 binding to pRb results in hyper-phosphorylation of pRb and release of E2F transcription factors which activate genes for cell proliferation. Although HPV E6 and E7 can immortalize cells independently, their co-operative interactions substantially enhance immortalization efficiency.
We sought to silence HPV E6 and E7 gene expression and designed siRNAs to target the respective viral mRNAs. Our results indicate selective degradation of E6 and E7 mRNAs. Silencing was sustained for at least 4 days following a single dose of siRNA. E6 silencing induced accumulation of cellular p53 protein, transactivation of the cell cycle control p21 gene and reduced cell growth. In contrast, silencing of E7 induced apoptotic cell death. HPV-negative cells appeared unaffected by the anti-viral siRNAs. Thus we demonstrate for the first time (i) that siRNA can induce selective silencing of exogenous viral genes in mammalian cells, and (ii) that the process of siRNA interference does not interfere with the recovery of cellular regulatory systems previously inhibited by viral gene expression.
Results
Choice of siRNA sequences for viral gene silencing siRNA interference is likely to be influenced by secondary RNA structure and positioning of the cognate sequence within the intact mRNA molecule. The siRNAs chosen for this study are shown in Figure  1a . Control siRNA was included in every experiment and lacks homology with HPV E6 and E7. None of the siRNAs share homology with exons of known human genes. Each 21-nucleotide (nt) RNA was synthesized with symmetric 2-nt overhang composed of (2'-deoxy thymidine) to enhance nuclease resistance. siRNA was introduced into cells by transfection (see Materials and methods) and the transfection efficiency for each cell line is shown in Figure 1b. siRNA causes selective loss of HPV E6 and E7 mRNAs Little, if any change in viral mRNAs was observed in cells treated with control siRNA relative to non-treated controls. However, treatment with either E6 siRNA or with E7 siRNA induced a marked decrease in the respective E6 and E7 mRNA levels in both CaSki and SiHa cells (Figure 2) . Similar results were obtained by Northern blotting and by semi-quantitative RT -PCR, examples shown are for cells treated with control siRNA or E6 siRNA at 48 h (Figure 2a,b) . The decrease in E6 or E7 mRNA was maximal at 24 h and was sustained for at least 4 days. Importantly, cellular p53 mRNA levels appeared unaffected under all conditions (Figure 2c -e), indicating that anti-viral siRNAs do not activate generalised destruction of cellular mRNA. Approximately 70% reduction in E6 mRNA was observed following treatment with E6 siRNA (Figure 2c ). Since the transfection efficiencies were 70 -80% (Figure 1b) this represents close to complete loss of viral E6 mRNA in the transfected cells. In cells treated with E7 siRNA the reduction in E7 mRNA was approximately 50 -60% (Figure 2d ). Selective targeting of the individual viral mRNAs was demonstrated by the following observations: (i) p53 mRNA levels were resistant to E6 and E7 siRNA treatment ( Figure 2c ,d); (ii) E6 mRNA levels were resistant to E7 siRNA and control siRNA ( Figure  2d ,e); and (iii) E7 mRNA levels were resistant to E6 siRNA and control siRNA (Figure 2c ,e). Thus we conclude that treatment with E6 siRNA and E7 siRNA The process of RNA interference does not adversely affect mammalian cell growth regulatory mechanisms: activation of p53
If siRNA is to be developed as an experimental tool and/or for therapeutic applications it is important to establish that the process of RNA interference does not adversely affect cell control mechanisms. With this in mind we monitored cellular p53 protein in cells treated with siRNA. Both CaSKi and SiHa cells express wild type p53. In normal cells p53 levels are regulated by Hdm2-mediated degradation. However, Hdm2 is deficient in CaSKi and SiHa and the E6-mediated pathway is solely responsible for p53 degradation in these cells (Hengstermann et al., 2001 ). Loss of E6 should therefore stabilize p53 protein in cells treated with E6 siRNA.
By immunoblotting we observed accumulation of p53 protein after treatment with E6 siRNA ( Figure  3a ). The accumulation of p53 was largely nuclear as revealed by indirect immunofluorescence (Figure 4 ). Having shown that p53 mRNA levels remain constant in cells treated with E6 siRNA (Figure 2c ) we conclude that the increased p53 protein level (Figure 3a) represents stabilization of the p53 protein. However, p53 is a stress response protein and it was also necessary to ascertain that the process of siRNA transfection, by itself, is not sufficient to activate a p53 response. This was investigated by transfecting cells with either control siRNA or E7 siRNA. Although a slight increase in p53 protein levels was observed in both cases, the kinetics were much slower than for cells treated with E6 siRNA and there was no transactivation of p21, a p53 target gene (Figure 3b,c) .
In contrast, stabilization of p53 in cells treated with E6 siRNA is accompanied by induction of p21 expression ( Figure 3a) . Our results thus indicate that p53 becomes stabilized and is activated in E6 siRNA-treated cells. This effect is specific to E6 siRNA and reflects selective E6 gene silencing rather than a generalized stress response. The p21 protein is a cell cycle inhibitor and induces G1 cell cycle arrest by regulating pRb function (Hietenan et al., 2000) . Although cell growth was reduced in E6 siRNA-treated cells expressing p21, no substantial G1 arrest was observed by FACS analysis (approximately 10% relative to controls). A likely explanation is that p21-mediated effects were compromised due to sustained inactivation of pRb by E7. This implies dominance of E7 protein over E6 siRNA for cell cycle arrest.
E7 silencing results in de-phosphorylation of pRb
Binding of HPV E7 to pRb and Rb-related cellular proteins results in their hyper-phosphorylation and release of E2F transcription factors (see Introduction). Therefore silencing of HPV E7 may cause reduction or loss of the hyper-phosphorylated form of pRb. Indeed, this proved to be the case. Treatment of SiHa cells with E7 siRNA resulted in loss of the upper band of pRb as detected by immunoblotting ( Figure 5 ). This upper band corresponds to hyper-phosphorylated pRb which migrates more slowly than the hypo-phosphorylated protein on gel electrophoresis. In contrast, cells treated with either control siRNA or E6 siRNA retained both phosphorylated forms of pRb (as indicated by the doublets of hyper-phosphorylated plus hypo-phosphorylated pRb protein shown in Figure 5 ). These observations confirm selective silencing of the HPV E7 gene in cells treated with E7 siRNA.
E7 siRNA induces apoptosis of HPV-positive cells
Ideally, a therapeutic agent for use in treatment of human cervical cancer should selectively target the tumour cells for destruction without affecting surrounding normal tissues. In the case of HPVpositive cervical carcinomas this is a realistic objective since the driving force of malignancy is exogenous. Both HPV E6 and E7 are known to influence the cellular apoptotic response (zur Hausen, 2000) . Having demonstrated the feasibility of selectively silencing these two exogenous viral genes using siRNA (see above) we next asked if viral gene silencing could induce selective killing of the HPV-positive cells. Application of E6 siRNA caused cell growth suppression but no significant cell death (Figure 6b,f) . In contrast E7 siRNA caused the cells to round up and to undergo apoptosis (Figure 6c,f) . We considered the possibility that E7 siRNA might induce apoptotic cell death through targeting some hitherto unidentified endogenous gene important for cell viability. However, when E7 siRNA was applied to HPV-negative primary human diploid fibroblasts (NDF) and human colorectal carcinoma HCT116 cells no adverse effects on cell growth or viability were observed (Figure 6d ,e, and cell growth analyses). Thus we conclude that apoptosis in cells treated with E7 siRNA is initiated by silencing of HPV E7 gene expression and is therefore selective for HPV-positive carcinoma cells.
Others have shown that p53 availability is important for CD95-induced apoptosis in primary human keratinocytes immortalized with E6 and/or E7 and treated with proteasome inhibitor to stabilize p53 (Aguilar-Lemarroy et al., 2002). However, meaningful comparison with our present results cannot be drawn since the two experimental systems are fundamentally different. Indeed, a number of conflicting observations on apoptotic effects following blockage of HPV E6 and E7 are difficult to reconcile (zur Hausen, 2000) . Our present results confirm and greatly extend a previous study using antisense oligonucleotides to target the start codons of HPV-18 E6 and E7: Repeated dosage with E7 antisense caused selective killing of HPVpositive cells, as determined by simple light microscopy, whereas E6 antisense had no apparent effect (Steele et al., 1993) . In future studies the application of RNA interference may enable more detailed analysis of E6 and E7 functions at different stages during progression from HPV infection to malignancy.
Discussion
RNA interference, anti-sense RNA and ribozymes all operate at the post-transcriptional level to suppress gene expression. However, the process of RNA interference is several orders of magnitude more efficient than anti-sense or ribozyme strategies (Elbashir et al., 2001) . It also consumes high levels of cellular ATP (Nykanen et al., 2001) . It is therefore possible that RNA interference may cause imbalance within normal cellular biochemical processes and regulatory systems. However, our present findings indicate that this is not the case. We demonstrate that RNA interference does not block the recovery of endogenous regulatory systems during siRNA-primed silencing of viral genes in human cells. In the case of HPV E6 silencing the p53 protein was stabilized, the p21 cell cycle control gene was expressed and cell growth reduced. E7 silencing, on the other hand, initiated the process of apoptosis (which also consumes high levels of ATP accompanied by loss of mitochondrial integrity). Thus we show that cells undergoing RNA interference retain the ability to perform highly complex and biochemically integrated processes involved in differential gene expression and apoptosis. This is an important and novel observation demonstrating that the process of RNA interference does not compromise these critical functions in mammalian cells.
The ability to selectively silence mammalian gene expression using siRNA opens new and exciting routes to the understanding of mammalian cell biology and its pathology. However, it cannot be assumed that all genes will prove equally susceptible to RNA interference. The process is dependent upon mRNA accessibility and, within the target mRNA molecule, Figure 5 E7 siRNA induces selective loss of hyper-phosphorylated cellular pRb. Lysates from SiHa cells treated with control siRNA, E6 siRNA or E7 siRNA were probed for pRb by immunoblotting. Rb*=hyper-phosphorylated pRb; Rb=hypo-phosphorylated pRb siRNA silencing of HPV16 E6 and E7 gene expression M Jiang and J Milner upon accessibility of the short internal nucleotide sequence homologous to the siRNA primer. It follows that various factors will influence the vulnerability of a given mRNA to siRNA-mediated degradation, including secondary structures of the mRNA, and proteins which package mRNA for translocation within the cell (see Orphanides and Reinberg, 2002 , for review of eukaryotic mRNA processing). Other protein-mRNA interactions are also relevant, including proteins which can direct a given mRNA to a specific sub-cellular locus (Gu et al., 2002) , and those mRNAs which can be bound by the proteins they encode, such as p53 (Mosner et al., 1995) .
Here we demonstrate that pathogenic viral mRNAs encoded by HPV are vulnerable to RNA interference in mammalian cells. Selective silencing of exogenous viral gene expression by siRNA is particularly relevant to human disease. First, for fundamental research into the pathogenesis of mammalian viruses and for enabling identification of novel therapeutic targets. In addition, siRNA itself may be developed as a novel anti-viral agent to counter viral infection and disease. RNA interference is very efficient. We now show that viral gene silencing by a single dose of anti-viral siRNA can be sustained long enough to allow recovery of cellular regulatory systems. In the case of HPV-positive human carcinoma cells this leads to selective killing of the cancer cells.
For therapeutic applications of siRNA, the target mRNA should ideally be recognized via evolutionary conserved nucleotide sequence(s). This minimizes potential for loss of homology between the siRNA and the target mRNA due to genetic mutation. Polymorphic targets should also be avoided. Consideration should also be given to the possibility that different cell types may vary in their response to the introduction of short double-stranded siRNA molecules. A particularly apposite example concerns the ability of E6 and E7 proteins to disrupt the expression of interferons and of interferon-inducible genes in HPV-infected cells (reviewed in Koromilas et al., 2001) . Indeed, such an effect may have contributed to the high efficacy of siRNA-mediated effects observed in the present study.
Our observations indicate that E7 siRNA has major therapeutic potential for the treatment, and possibly prevention of human cervical cancer. We believe that other pathogenic viral agents may similarly be silenced by administration of the relevant siRNAs. Thus our results identify siRNA as a powerful tool (i) for studying the molecular and cellular pathology of viral-induced diseases, and (ii) for the development of novel anti-viral therapies. For HPV-positive human cervical carcinoma our observations indicate that the HPV-E7 gene is the target of choice. and 50 mM NaCl) for 1 min at 908C followed by 1 h at 378C. For quantitation of mRNA by Northern blotting 0.3 mg of total mRNA, prepared using Oligotex (Qiagen), was run with size markers on a 1% agarose gel at room temperature under standard conditions. HPV16 E6 mRNA was detected using radiolabelled 32 P-HPV E6 cDNAs as probes and visualized by autoradiography. Total cellular RNA was prepared using the RNeasy kit (Qiagen). For RT -PCR the Reverse-iT onestep kit (Advanced Biotechnologies) was employed. For RT -PCR reactions 0.1 mg total RNA was used. For E6 mRNA amplification, the primers 5'-CGGAATTCATGCACCAAA-AGAGAACTGCA-3' and 5'-CCCAAGCTTACAGCTGGG-TTTCTCTACG-3' were used in the thermal cycle: 478C, 30 min; 948C, 2 min; then 35 cycles of 948C 45 s, 558C 45 s and 728C 1 min; followed by 728C for 5 min. For E7 mRNA amplification the primers were 5'-CGGAATTCATGCATG-GAGATACACCTACAT-3' and 5'-CGGGAAGCTTATGG-TTTCTGAGAACAGATGG-3', and the thermal cycle as 478C, 30 min; 948C, 2 min; then 30 cycles of 948C 45 s; 588C 45 s and 728C 2 min; followed by 728C, 5 min. For p53 mRNA, the primers 5'ATGGAGGAGCCGCAGTCAGAT3' and 5'TCAGTCTGAGTCAGGCCCTTC3' were used, and the thermal cycle as follows: 478C, 30 min; 948C, 2 min; then 35 cycles of 948C 45 s, 588C 45 s and 728C 2 min; followed by 728C for 5 min. For semi-quantitative RT -PCR 100 ng total cellular RNA was diluted 1/20 and 1/400. Northern blots were repeated twice, and semi-quantitative RT -PCRs were repeated two to four times with reproducible results.
Cell lines and transfections
CaSKi and SiHa epithelial cell lines are derived from human cervical carcinomas and contain integrated HPV-16 genome, about 600 copies (CaSKi) and one to two copies (SiHa). CaSKi cells were cultured in RPMI plus 10% foetal calf serum (FCS, Life Technologies). SiHa cells were cultured in MEM plus 10% FCS, 1.0 mM sodium pyruvate, and 0.1 mM non-essential amino acids. NDF were cultured in MEM plus 15% FCS, 1.0 mM sodium pyruvate, and 0.2 mM essential amino acids. HCT116 were in DMEM with 10% FCS. All the cell lines were cultured with penicillin 100 units ml 71 and streptomycin 100 mg ml 71 at 378C in 5% CO 2 in air. For transfection the cells were trypsinized and subbed into 6-well plates (10 cm 2 ) without antibiotics, 1.5610 5 cells per well. After 24 h the cells were transfected with siRNA formulated into liposomes (Oligofectamine, Life Technologies) according to the manufacturer's instructions. siRNA concentration was 0.58 mg per 1.5610 5 cells per well. The final volume of culture medium was 1.5 ml per well. Cells were harvested for analysis at various times thereafter as indicated in the results. Each experiment was carried out four or more times. Transfection efficiencies were established by transfecting with liposomes containing FITC-dextran (FD-150; Sigma).
Immunoblotting
Transfected cells were trypsinized, washed in PBS and an aliquot removed for cell counting. The remaining cells were lysed in 50 ml lysis buffer (150 mM NaCl; 0.5% NP40; 50 mM Tris pH 8.0) on ice for 30 min. Samples were diluted 1 : 1 in 46 strength Laemlli's buffer. Proteins were resolved by 15% SDS -PAGE and electroblotted onto nitrocellulose membrane for antibody detection. Molecular weight markers and purified recombinant human p53 were included as markers as necessary. Monoclonal antibody DO-1 (Oncogene) was used to detect human p53 protein; anti-p21 (SX118) and anti-pRb (G3-245; PharMingen) were used to detect p21 and pRb proteins respectively. Actin was detected using polyclonal antibody (Sigma). Note that it was not possible to monitor HPV E6 or E7 protein levels since no antibodies are available for their reliable quantitation. Visualization of bound antibodies was enhanced by chemiluminescence (Roche). Signal quantitation was by scanning signals in the linear range.
Cell growth, cell cycle analysis and apoptosis
Cell growth curves were determined by cell counting. For cell cycle analysis the cells were harvested, washed with PBS and fixed in 90% ethanol overnight at 7208C. The fixed cells were pelleted, washed in PBS and resuspended in PBS containing 0.1 mg/ml propidium iodide with 200 U/ml RNase A and analysed by FACS. Apoptotic cells were identified using annexin-V-Fluos (Boehringer) following the manufacturer's protocol.
Note added in proof
It has been recently shown that SiRNA inhibits HIV-1 viral gene expression (Novina et al., 2002) .
